MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a scientific stage pharmaceutical firm dedicated to expanding healthy and balanced life expectancy, today revealed that the very first patient has been enlisted in the Company’s Phase 2 medical test of lead candidate MYMD-1, an oral immune regulator medicine, as a therapy for delaying aging and also broadening healthy and balanced life-span.
The key endpoint for the Phase 2 double-blind, placebo-controlled professional trial is to attain a decrease in the flowing levels of (TNF-α), lump necrosis variable receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the healthy proteins in the body that create swelling and also aid trigger the process of aging. The additional actions of the test will certainly be the safety, tolerability, as well as pharmacokinetics in this population of patients.
” In a Phase 1 clinical test of MYMD-1, we showed the drug’s statistically considerable efficacy in lowering degrees of TNF-α, a principal in creating pathological aging, in the blood. The FDA has actually authorized TNF-α reduction as the primary endpoint for our Stage 2 research study, which we believe positions us well for an effective Stage 2 end result,” stated Chris Chapman, M.D., Head Of State, Director as well as Principal Medical Officer of MyMD. “The initiation of individual registration in this research study advancements our mission to slow down the aging procedure, avoid loss of muscle mass cells in aging, limitation frailty, and also extend healthy lifespan.”
MyMD has stated that there are no FDA-approved medicines for treating aging disorders and also extending healthy and balanced lifespan people, a market anticipated to be a minimum of $600 billion by 20251 according to a significant financial investment bank. TNF-α blockers are one of the most proposed medications by income, a global market of approximately $40 billion annually,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would raise life span by one year is worth $38 trillion as well as by ten years is worth $367 trillion.
Along with aging, MYMD-1’s distinctive activity in managing the body immune system as well as dealing with chronic inflammation is being established for the treatment of autoimmune condition, consisting of rheumatoid arthritis (RA), several sclerosis (MS), diabetic issues, as well as inflammatory digestive tract disease.
” We plan to begin composing procedures for a Stage 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The increasing occurrence of rheumatoid arthritis as well as other autoimmune as well as inflammatory illness are driving need for TNF inhibitors like MYMD-1, and we believe our orally provided medicine with very low toxicity would certainly be disruptive to the $60 billion market for RA if accepted by the FDA for this indication.”
Rheumatoid joint inflammation impacts approximately 40 million people around the world.4.
Initially developed for autoimmune conditions, MYMD-1’s key purpose is to slow the aging procedure, prevent sarcopenia and frailty, as well as expand healthy and balanced lifespan. Since it can go across the blood-brain barrier and also access to the main nerves (CNS), MYMD-1 is likewise positioned to be a feasible therapy for brain-related conditions. Its mechanism of activity and also effectiveness in illness including numerous sclerosis (MS) and thyroiditis have been researched through cooperations with several scholastic establishments. MYMD-1 is additionally revealing guarantee in pre-clinical studies as a potential treatment for blog post- COVID-19 issues and also as an anti-fibrotic as well as anti-proliferation healing.
MYMD-1 has shown performance in pre-clinical studies in managing the immune system by carrying out as a selective prevention of tumor necrosis factor-alpha (TNF-α), a driver of persistent swelling. Unlike other therapies, MYMD-1 has actually been shown in these pre-clinical studies to uniquely block TNF-α when it becomes overactivated in autoimmune illness and cytokine storms, however not block it from doing its normal task of being a very first responder to any kind of routine kind of modest infection. MYMD-1’s simplicity of dental dosing is another differentiator contrasted to presently available TNF-α blockers, every one of which require distribution by shot or infusion. No accepted TNF prevention has actually ever been dosed orally. Furthermore, the medicine is not immunosuppressive and has actually not been revealed to cause the significant side effects common with standard therapies that deal with swelling.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional phase pharmaceutical company devoted to expanding healthy life expectancy, is concentrated on developing two unique healing platforms that deal with the root causes of condition as opposed to just addressing the symptoms. MYMD-1 is a medicine system based on a scientific phase small molecule that manages the body immune system to regulate TNF-α, which drives chronic inflammation, and also various other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, boost long life, as well as treat autoimmune conditions and COVID-19- linked anxiety. The Business’s second medicine platform, Supera-CBD, is being created to treat chronic discomfort, addiction as well as epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) and also is being created to deal with and surpass the quickly growing CBD market, which includes both FDA authorized medicines and also CBD products not presently managed as drugs. To find out more, go to www.mymd.com.